Nynomic Full Year 2023 Earnings: EPS Misses Expectations
Nynomic (ETR:M7U) Full Year 2023 Results
Key Financial Results
- Revenue: €119.1m (up 1.9% from FY 2022).
- Net income: €9.31m (up 25% from FY 2022).
- Profit margin: 7.8% (up from 6.4% in FY 2022).
- EPS: €1.47 (up from €1.26 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nynomic EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.2%.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany.
Performance of the German Electronic industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Nynomic, and understanding it should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if Nynomic might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:M7U
Nynomic
Manufactures and sells products for the spectroscopy, sensor technology, laboratory automation and medical technology, agriculture and environmental technology, and industrial markets worldwide.
Flawless balance sheet with solid track record.